ERBB2 and breast cancer: Exclusive use of non-aspirin NSAIDs was associated with a slightly higher risk of Luminal A (ER-positive, PR-positive, and HER2-negative) and triple-negative (ER-negative, PR-negative, and HER2-negative) breast cancer.